stockrow
Friday 6 November 2026
Export SNY’s income statement to Excel — free account
Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
46.12
0.79
−1.68%
Follow SNY
Alert me
Sanofi (SNY) EBITDA
Sanofi's EBITDA for fiscal 2025 was $16.3B, up 34.3% from $12.1B in fiscal 2024. Over the twelve months to 30 September 2026 it was $11.1B. Over the past ten years it has ranged from $11.2B (fiscal 2017) to $20.6B (fiscal 2020); the current reading is higher than 91% of that period. Sanofi ranks 12th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $16.3B | 34.34% |
| FY2024 | $12.1B | (18.13%) |
| FY2023 | $14.8B | 3.18% |
| FY2022 | $14.3B | 3.72% |
| FY2021 | $13.8B | (32.95%) |
| FY2020 | $20.6B | 31.89% |
| FY2019 | $15.6B | 38.37% |
| FY2018 | $11.3B | 0.44% |
| FY2017 | $11.2B | (0.08%) |
| FY2016 | $11.2B | (4.59%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $5.0B | 100.11% |
| Jun 2026 | $2.5B | 2.39% |
| Mar 2026 | $2.4B | 117.01% |
| Dec 2025 | $1.1B | (73.97%) |
| 39 more quarters | Free account |
Against its own ten years
Low $11.2B
High $20.6B
Ten-year median
$13.8B
Current reading's percentile
91
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $26.5B |
| NVS Novartis AG compare | $22.1B |
| AZN AstraZeneca PLC compare | $21.2B |
| PFE Pfizer Inc. compare | $20.1B |
| AMGN Amgen Inc. compare | $16.5B |
| BMY Bristol Myers Squibb Company compare | $14.1B |
| GSK GSK PLC Sponsored ADR compare | $12.2B |
| SNY Sanofi | $11.1B |
| GILD Gilead Sciences, Inc. compare | $451.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SNY
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement